REGENERON PHARMAC.DL-,001/ US75886F1075 /
| 2024-04-25 9:27:21 PM | Chg. -18.800 | Volume | Bid7:50:47 AM | Ask7:50:47 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 832.000EUR | -2.21% | 73 Turnover: 60,526 |
827.800Bid Size: 7 | 836.000Ask Size: 7 | 91.11 bill.EUR | - | - |
GlobeNewswire
04-25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
04-24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
04-22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
04-07
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...
GlobeNewswire
04-01
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...
GlobeNewswire
03-13
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientif...
GlobeNewswire
03-11
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High C...
GlobeNewswire
03-08
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) a...
GlobeNewswire
02-23
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire
02-21
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Re...
GlobeNewswire
02-16
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
GlobeNewswire
02-02
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
02-02
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire
01-30
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platf...
GlobeNewswire
01-25
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year an...
GlobeNewswire
01-24
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Mil...
GlobeNewswire
01-16
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with ...
GlobeNewswire
01-05
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Confe...
GlobeNewswire
2023-12-18
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-11
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
GlobeNewswire
2023-12-11
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and ...
